PAD

ARCA Recycling, a Subsidiary of JanOne Inc., Launches Two Recycling Programs in California in Effort to Reduce GHG Emissions

Retrieved on: 
Wednesday, October 27, 2021
Foam, Peripheral artery disease, ARCA, Technology, Disease, Annual report, Neuropathic pain, Chlorofluorocarbon, Resource Conservation and Recovery Act, Private Securities Litigation Reform Act, NASDAQ, FDA, Opioid, Sumathi Best Television Current Reporting Award, Terminology, Education, U.S. Securities and Exchange Commission, SEC, Recycling, Prescription, Glass, RAD, ODP, GHG, Company, Form 10-K, United States Environmental Protection Agency, Pain, Solution, Nasdaq, Metal, PAD, Plastic

ARCA anticipates recycling 10,000 total appliances through these programs, resulting in landfill diversion of over 1.2 million lbs.

Key Points: 
  • ARCA anticipates recycling 10,000 total appliances through these programs, resulting in landfill diversion of over 1.2 million lbs.
  • Foam is sent to a co-generation facility where it is incinerated, capturing 100% of the remaining GHG emissions.
  • ARCA Recycling is the largest implementer of appliance recycling and replacement programs in North America, with over 100 programs in operation.
  • To learn more about ARCA Recycling's capabilities around appliance recycling or income-qualified appliance direct install replacement programs, please contact the company at [email protected] .

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Safety, Cytokine release syndrome, MD, Blood, Shock, RJX, Cancer, Inflammation, Disease, CRS, NIPPV, Patient, Private Securities Litigation Reform Act, Part, FDA, Sepsis, Multiple organ dysfunction syndrome, Acute respiratory distress syndrome, SEC, Communication, Adult, Forward-looking statement, LLC, Standard of care, Clinical trial, CEO, COVID-19, Health, PAD, Risk, DSMB, Pneumonia, Pharmaceutical industry, Rejuveinix (RJX), Reven Holdings, Inc., REJUVEINIX (RJX), REVEN HOLDINGS, INC.

Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.

Key Points: 
  • Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.
  • Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • This FDA-approved controlled clinical trial is aimed at evaluating the efficacy and safety of RJX in side-by-side comparison with a placebo as an adjunct to standard of care in hospitalized COVID-19 patients.
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

First-Time Candidate Jodi Merriday Announces Key Endorsements

Retrieved on: 
Tuesday, October 19, 2021
Slate, Well, United States Senate Committee on Homeland Security and Governmental Affairs, London, Interview, City, Private sector, Hand, Black Slate, APS, Association, Disclosure, Organization, PAD, Temple University, Committee, Bethel Merriday, Ombudsman, Education, APD, Community, Georgia, London School of Economics, Atlanta City Council, Candidate, Social justice, Century, Animal, Private investigator, Nightclub

ATLANTA, Oct. 19, 2021 /PRNewswire-PRWeb/ -- Community leader Jodi Merriday, candidate for the Atlanta City Council Post 3 At-Large seat, announces key endorsements heading into the final weeks before the Nov. 2 election.

Key Points: 
  • ATLANTA, Oct. 19, 2021 /PRNewswire-PRWeb/ -- Community leader Jodi Merriday, candidate for the Atlanta City Council Post 3 At-Large seat, announces key endorsements heading into the final weeks before the Nov. 2 election.
  • "The Candidate Screening Committee was very impressed with your knowledge of the issues.
  • "I am proud to have been endorsed by so many prominent organizations as I finish this sprint into November," Merriday said.
  • Merriday, a public and higher education professional, corporate diversity trainer, and former Ombudsmen for Atlanta Public Schools, launched her citywide candidacy with public safety as her primary focus.

ARCA Recycling, a Subsidiary of JanOne Inc., Sees Major Increase in Appliance Replacement Contracts, Estimated to Push Revenue of Replacement Programs to Nearly $20 Million, in Addition to Recycling Business

Retrieved on: 
Tuesday, October 19, 2021
Recycling, Pain, NASDAQ, Form 10-K, Technology, Private Securities Litigation Reform Act, Sumathi Best Television Current Reporting Award, Neuropathic pain, Sarbanes–Oxley Act, Growth, PAD, Appliance, Terminology, Annual report, Disease, Contract, U.S. Securities and Exchange Commission, Prescription, Education, FDA, Nasdaq, Opioid, Peripheral artery disease, SEC, Solution, ARCA, Company, Consumer electronics

ARCA Recycling currently operates over 40 replacement programs throughout the U.S. and Canada, with approximately 30,000 appliances replaced annually.

Key Points: 
  • ARCA Recycling currently operates over 40 replacement programs throughout the U.S. and Canada, with approximately 30,000 appliances replaced annually.
  • Appliance replacement programs reduce the energy burden on income-eligible customers, save energy and reduce GHG-emissions due to the proper recycling of older appliances.
  • ARCA Recycling is the largest implementer of appliance recycling and replacement programs in North America, with over 100 programs in operation.
  • To learn more about ARCA Recycling's capabilities around appliance recycling or income-qualified appliance direct install replacement programs, please contact the company at [email protected] .

ARCA Recycling, a Subsidiary of JanOne Inc., Opens Recycling Center in Michigan to Support New Multi-Year Contracts Totaling Millions in Revenue

Retrieved on: 
Tuesday, October 12, 2021
NASDAQ, Company, Private Securities Litigation Reform Act, Pain, Sarbanes–Oxley Act, ARCA, Neuropathic pain, Prescription, United States Environmental Protection Agency, Contract, Form 10-K, Program, Peripheral artery disease, Growth, Annual report, Education, SEC, Terminology, RAD, FDA, U.S. Securities and Exchange Commission, Opioid, Sumathi Best Television Current Reporting Award, Recycling, Solution, Compliance, Disease, Technology, Nasdaq, PAD, Pharmaceutical industry

MINNEAPOLIS, Oct. 12, 2021 /PRNewswire/ --ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state.

Key Points: 
  • MINNEAPOLIS, Oct. 12, 2021 /PRNewswire/ --ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state.
  • ARCA was recently awarded multiple contracts to provide appliance recycling services for major Michigan electric utilities through the end of 2022; ARCA is pursuing other major contracts in the region to drive volume through the new facility.
  • All appliances from the utility-sponsored appliance recycling program are processed by ARCA in compliance with the U.S. Environmental Protection Agency's Responsible Appliance Disposal (RAD) program guidelines.
  • ARCA Recycling is the largest implementer of appliance recycling programs in North America, with over 90 utility-sponsored programs in operation.

Late-breaking Data From PROMISE I Study On LimFlow System Confirm Excellent Sustained Outcomes In Patients With No-option Chronic Limb-threatening Ischemia

Retrieved on: 
Thursday, October 7, 2021
Wound healing, Freedom, Coronary artery disease, Patient, Prognosis, Leg, SA, AFS, Death, Angioplasty, SAN, Vein, Professor, Department, Conference, Multimedia, Amputation, Survival, Foot, Diabetes, Chronic pain, Mortality, Chronic limb threatening ischemia, Population, LAS, MD, Sepsis, FFA, Quality of life, VIVA, Artery, Infection, Disease, Obesity, Surgery, PAD, Peripheral artery disease, Medical imaging, Pharmaceutical industry, Health insurance, Online shopping

PROMISE I is a multi-center, prospective, single-arm study of the LimFlow System, conducted at seven study centers across the U.S. All of the 32 patients enrolled in the study had non-healing wounds on the target foot.

Key Points: 
  • PROMISE I is a multi-center, prospective, single-arm study of the LimFlow System, conducted at seven study centers across the U.S. All of the 32 patients enrolled in the study had non-healing wounds on the target foot.
  • The LimFlow System received the Conformit Europenne (CE) Mark in October 2016 and is currently only commercially available in Europe.
  • The PROMISE II study is currently enrolling patients at up to across 22 sites in the U.S. and Japan.
  • For more information on LimFlow and the LimFlow System, please visit www.limflow.com .

ARCA Recycling, a Subsidiary of JanOne Inc., Awarded Recycling Contracts in Pennsylvania With Total Estimated Value of 20 Million Dollars for Work in the State to Continue Through 2026

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, Company, Private Securities Litigation Reform Act, Pain, Sarbanes–Oxley Act, PAD, ARCA, Neuropathic pain, Prescription, Contract, Form 10-K, Peripheral artery disease, Education, Annual report, SEC, Terminology, FDA, U.S. Securities and Exchange Commission, Opioid, Sumathi Best Television Current Reporting Award, Solution, Partnership, Disease, Technology, Recycling, Nasdaq, Pharmaceutical industry

ARCA Recycling works in partnership with several major electric utility companies in the state and ARCA aims to recycle over 30,000 refrigerators and freezers from the state annually.

Key Points: 
  • ARCA Recycling works in partnership with several major electric utility companies in the state and ARCA aims to recycle over 30,000 refrigerators and freezers from the state annually.
  • ARCA estimates the total value of contracts awarded in Pennsylvania to be approximately $20 million over the next five years.
  • Currently, ARCA Recycling operates three recycling centers in Pennsylvania, with facilities in Pittsburgh, Philadelphia and Mechanicsburg.
  • ARCA Recycling is the largest implementator of appliance recycling programs in North America, with over 90 utility programs in operation.

New Round of Late-Breaking Clinical Trials Announced at VIVA21

Retrieved on: 
Wednesday, October 6, 2021
Consensus, Mortality, VIVA, CTO, Recurrence, Disrupt, SEB, Vascular disease, Freedom, Kaplan–Meier estimator, Bed, Medtronic, Blood vessel, Wynn Las Vegas, Amputation, Classification, Safety, Perforation, IVL, Chronic kidney disease, Wound healing, Multimedia, DCB Bank, Boston Scientific, DES, Brachiocephalic, Diabetes, AFS, Shock wave, Ascending limb of loop of Henle, Awareness, BMS, Observational study, Transatlantic, TASC, SEBS, PTA, EQ-5D, Atherectomy, Complex, DCB, HIV disease progression rates, Arm, Peripheral artery disease, Time Machine, Calcification, Education, Treatment, Death, Iliac, PAD, Prevalence, Research, AVF, Operational technology, Ioctl, Medical imaging, Pharmaceutical industry

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • Participants were randomized to treatment with IN.PACT AV DCB (Medtronic; n = 170) or standard uncoated percutaneous transluminal angioplasty (PTA; n = 160).
  • Benefits were seen in all other subgroups, although the treatment effect was not statistically significant.
  • This is the largest randomized trial of device treatment for critical limb ischemia in this arterial segment to date.

Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

Retrieved on: 
Wednesday, October 6, 2021
Mortality, Securities Act of 1933, PPA, VIVA, Risk, Annual report, Emory Saint Joseph's Hospital, Security (finance), Drug Quality and Security Act, Plaque, Health, Intention, Hospital, U.S. Securities and Exchange Commission, Patient, BSX, Boston Scientific, SFA, Physician, Boston, PAD, Twitter, Swelling, Life, Pain, Paclitaxel, Artery, Science, Technology, Peripheral artery disease, Department, Forward-looking statement, Securities Exchange Act of 1934, Intellectual property, BMS, Quality of life, NYSE, Time, Popliteal artery, Pharmaceutical industry, Medical imaging

LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.

Key Points: 
  • LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
  • Data presented included one-year results from the EMINENT trial, which demonstrated superiority of the Eluvia stent compared to self-expanding bare metal stents (BMS) for the treatment of patients with peripheral artery disease (PAD) and superficial femoral artery (SFA) or popliteal artery (PPA) lesions up to 210 mm in length.
  • The study enrolled 775 patients, making it the largest randomized trial of a drug-eluting stent for the treatment of PAD to date.
  • Further, there was no significant difference in major adverse events or all-cause mortality rates between patients treated with the Eluvia stent and those treated with BMS through one year.

Fingerprint PAD Competition: First place for DERMALOG

Retrieved on: 
Wednesday, October 6, 2021
Efficiency, Solution, Person, Software, PAD, Identity theft, University, Face, University of Cagliari, Liveness, Fraud, Technology, Algorithm, Security printing

HAMBURG, Germany, Oct. 6, 2021 /PRNewswire/ -- Plastic fingers or other artificial fingerprints can trick fingerprint scanners. There are many cases where unauthorized persons have gained access to smartphones, databases and other protected areas. This is possible by copying the fingerprint pattern of a real-life person onto plastic or other materials, creating an artificial finger or fingerprint overlay that can be used to spoof fingerprint-based systems with a false identity.

Key Points: 
  • The software of the German company DERMALOG is again number 1 in protecting identification systems against fake fingerprints.
  • HAMBURG, Germany, Oct. 6, 2021 /PRNewswire/ --Plastic fingers or other artificial fingerprints can trick fingerprint scanners.
  • First place again was awarded to DERMALOG from Germany with the highest overall score in detecting fake fingerprints.
  • DERMALOG is the largest German manufacturer of biometric systems for fingerprint, face and iris identification, with 250 large-scale installations in more than 100 countries.